# Associations between psychedelic use and adverse outcomes in substance use disorders: a real-world EHR-based cohort study

## TL;DR

This study finds that psychedelic use, especially with other treatments, is linked to fewer bad outcomes for people with substance use disorders.

## Contribution

The study provides real-world evidence of reduced adverse outcomes from psychedelic use in SUD treatment.

## Key findings

- Psychedelic use was associated with significantly lower rates of overdose, relapse, and hospitalizations.
- Combining psychedelics with anesthetics and outpatient services reduced mental health crises the most.
- Results were consistent across sensitivity analyses and comparisons to other treatments.

## Abstract

To examine associations between psychedelic use and adverse health outcomes, including overdose, relapse, mental health crises, and hospitalizations, among individuals with substance use disorders (SUD), and to compare these outcomes across different treatment modalities including anesthetics and outpatient SUD services.

Retrospective cohort study using propensity score-weighted quasi-Poisson regression models to estimate adjusted incidence rate ratios (aIRRs).

Data were drawn from Oracle EHR Real-World Data™ comprising 138 U.S. health systems restricted to those ≥12 years old from January 1, 2000, to August 31, 2023.

3,209,798 patients with a documented SUD diagnosis from 2000 to 2023. Patients with a prior history of psychedelic use or hallucinogen-related diagnoses were excluded. The final cohort included 8,514 new psychedelic users and over 3.2 million non-users.

Exposures were captured during a 3-month post-index period and included outpatient psychedelic prescriptions or procedures (primarily ketamine), general anesthetic outpatient prescriptions, and outpatient SUD services. Outcomes, assessed over 2 years, included SUD-related hospitalizations/emergency department (ED) visits, mental health crises, all-drug overdoses, and relapse. Propensity scores accounted for demographic, clinical, and behavioral confounders.

Psychedelic use was associated with significantly reduced rates of all adverse outcomes, including all-drug overdose (aIRR F;= F;0.48; 95% CI: 0.37-0.63), relapse (aIRR F;= F;0.68; 0.60-0.77), SUD hospitalizations/ED visits (aIRR F;= F;0.76; 0.69-0.82), and mental health crises (aIRR F;= F;0.82; 0.73-0.92), compared to no treatment. The combination of psychedelics, anesthetics, and outpatient services was associated with the strongest reduction in mental health crises (aIRR F;= F;0.21; 0.06-0.77). Trends were consistent in sensitivity analyses including patients with mental health conditions and comparisons to medication-assisted treatment.

In this large national cohort, psychedelic use, particularly when combined with anesthetic and outpatient care, was associated with reduced adverse health outcomes among people with SUD. These findings support further investigation into psychedelic-based interventions within integrated treatment frameworks.